Chimerix (CMRX) has risen sharply, recording gains of 4.61% in the past 4 weeks. However, the stock has corrected -5.07% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.21% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Chimerix, Inc. has dropped 8.49% during the last 3-month period . Year-to-Date the stock performance stands at -51.84%. The stock has recorded a 20-day Moving Average of 1.58% and the 50-Day Moving Average is 6.45%.
Chimerix (NASDAQ:CMRX): The stock opened at $4.35 on Friday but the bulls could not build on the opening and the stock topped out at $4.38 for the day. The stock traded down to $4.24 during the day, due to lack of any buying support eventually closed down at $4.31 with a loss of -1.15% for the day. The stock had closed at $4.36 on the previous day. The total traded volume was 241,007 shares.
Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).